Bio-Techne Corporation cash flow to debt ratio of 101.03% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Bio-Techne Corporation's free cash flow has increased 2.60% from $256.55M last year to $263.22M, signaling increasing performance

Bio-Techne Corporation's debt to equity ratio is 0.14, which means that the company's assets are healthy financed, signaling financial stability.

Bio-Techne Corporation's debt has decreased relative to shareholder equity from 0.23 last year to 0.14 today, signaling strengthened financials

Bio-Techne Corporation has a net debt to EBITDA ratio of 0.07x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Bio-Techne Corporation's interest coverage ratio of 46.60 indicates that earnings with good margin can cover interest payments on company debt

Bio-Techne Corporation's profit margin was 6.02% last year and is 14.97% this year, signaling increasing performance

Bio-Techne Corporation's short-term assets of $744.40M exceed its short-term liabilities of $163.70M

Bio-Techne Corporation's return on assets of 7.03% is higher than the 5.00% threshold, indicating efficient asset utilization

Bio-Techne Corporation's return on equity of 8.90%, is lower than 15.00%, indicating bad performance

Bio-Techne Corporation's operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Bio-Techne Corporation had positive net income in 5 out of 5 years, indicating stable and consistent earnings

Bio-Techne Corporation has positive free cash flow, indicating the company generates cash after capital expenditures

Bio-Techne Corporation has a free cash flow yield of 2.32%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Bio-Techne Corporation's yearly earnings has increased 147.77% since last year from $73.40M to $181.86M, signaling increasing performance

Bio-Techne Corporation's yearly revenue has decreased 0.38% since last year from $1.22B to $1.22B, signaling decreasing performance

ROIC 7.81% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

Bio-Techne Corporation's 3-year revenue CAGR of 2.25% is positive, indicating growing revenue over the past 3 years

Bio-Techne Corporation had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Bio-Techne Corporation had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

Bio-Techne Corporation is overvalued relative to its fair value price of 17.02 based on Base Cash Flow Valuation (DCF) model

Bio-Techne Corporation has an earnings yield of 1.61%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Bio-Techne Corporation is overvalued relative to its fair value price of 15.16 based on Base EBITDA Valuation model

Bio-Techne Corporation has an EV/EBITDA ratio of 33.17x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Bio-Techne Corporation is overvalued relative to its fair value price of 25.63 based on Base Earnings Fair Value model

Bio-Techne Corporation has a PEG-ratio over 1 which is considered overvalued

Bio-Techne Corporation has a price-to-book ratio of 5.37x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Bio-Techne Corporation has a price-to-sales ratio of 9.32x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue